About 25% of patients suffering from chronic spontaneous urticaria (CSU) are refractory to first-line therapy, making treatment challenging in these cases. There are limited options in the treatment ladder for urticaria as omalizumab is more effective in patients with raised immunoglobulin E levels; also, cost and feasibility of administration are limiting factors. Dose-related side effects often limit cyclosporine’s greater efficacy. We started tofacitinib for our 68-year-old patient who had been suffering from refractory CSU for the past 12 years and observed quick control of signs and symptoms starting within 2 weeks and good long-term control for over 9 months of which last 6 months were monotherapy.
约有 25% 的慢性自发性荨麻疹（CSU）患者对一线疗法难治，这使这些病例的治疗面临挑战。由于奥马珠单抗对免疫球蛋白 E 水平升高的患者更有效，因此荨麻疹治疗阶梯中的选择有限；此外，成本和用药可行性也是限制因素。与剂量相关的副作用往往限制了环孢素的疗效。68岁的患者患有难治性CSU已有12年之久，我们为他开始使用托法替尼，观察到他的症状和体征在2周内迅速得到控制，并在超过9个月的时间里得到了良好的长期控制，其中最后6个月为单药治疗。
{"title":"A novel pitch against the itch","authors":"Shruthi Pavana Janardhanan, Punit Saraogi","doi":"10.25259/ijsa_13_2024","DOIUrl":"https://doi.org/10.25259/ijsa_13_2024","url":null,"abstract":"About 25% of patients suffering from chronic spontaneous urticaria (CSU) are refractory to first-line therapy, making treatment challenging in these cases. There are limited options in the treatment ladder for urticaria as omalizumab is more effective in patients with raised immunoglobulin E levels; also, cost and feasibility of administration are limiting factors. Dose-related side effects often limit cyclosporine’s greater efficacy. We started tofacitinib for our 68-year-old patient who had been suffering from refractory CSU for the past 12 years and observed quick control of signs and symptoms starting within 2 weeks and good long-term control for over 9 months of which last 6 months were monotherapy.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":" 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141672396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lenvatinib, a multiple tyrosine receptor kinase inhibitor, and pembrolizumab, an anti-programmed cell death protein 1 humanized antibody, both are indicated in the treatment of renal cell carcinoma (RCC). Both these agents rarely produce cutaneous adverse events. In this instance, a RCC patient who received both medications and experienced a papulosquamous eruption as an uncommon cutaneous side effect of both medications is being reported. The potential drug triggers preceded the symptom onset and the observed symptom resolved on discontinuation of pembrolizumab.
{"title":"Pembrolizumab-induced resolving papulosquamous eruption: An enigmatic presentation in a patient with renal cell carcinoma","authors":"Avik Mondal","doi":"10.25259/ijsa_3_2024","DOIUrl":"https://doi.org/10.25259/ijsa_3_2024","url":null,"abstract":"Lenvatinib, a multiple tyrosine receptor kinase inhibitor, and pembrolizumab, an anti-programmed cell death protein 1 humanized antibody, both are indicated in the treatment of renal cell carcinoma (RCC). Both these agents rarely produce cutaneous adverse events. In this instance, a RCC patient who received both medications and experienced a papulosquamous eruption as an uncommon cutaneous side effect of both medications is being reported. The potential drug triggers preceded the symptom onset and the observed symptom resolved on discontinuation of pembrolizumab.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141678728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Symmetrical drug-related intertriginous and flexural exanthema without baboon syndrome due to paracetamol: An uncommon side effect of a common drug: A case report and a review of literature","authors":"Rinki Tayal, Nidhi Khatri, M. Siddiqui","doi":"10.25259/ijsa_30_2024","DOIUrl":"https://doi.org/10.25259/ijsa_30_2024","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"7 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141685757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hot car seat thermal burn: A must sought for differential diagnosis in summers","authors":"Ayesha Sitam, Prajnajit Tripathy, Nibedita Patro","doi":"10.25259/ijsa_31_2024","DOIUrl":"https://doi.org/10.25259/ijsa_31_2024","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141683952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Eczema and skin allergy-focus on research","authors":"D. Pandhi","doi":"10.25259/ijsa_29_2024","DOIUrl":"https://doi.org/10.25259/ijsa_29_2024","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"86 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141015785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ananya Pramanik, M. Panda, A. Panda, Akash Agarwal
{"title":"Dasatinib-induced hand foot syndrome followed by bosutinib-induced photoallergic contact dermatitis in a patient of chronic myeloid leukemia: A rare co-occurrence","authors":"Ananya Pramanik, M. Panda, A. Panda, Akash Agarwal","doi":"10.25259/ijsa_1_2024","DOIUrl":"https://doi.org/10.25259/ijsa_1_2024","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"40 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140366859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：